Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05456360 · ClinicalTrials.gov registry record · Phase 2
Implementation of Digital Vital Sign Monitoring to Decrease Sleep Interruption and Enhance Recovery in Phase II of the PROmoting Sleep, Patient Engagement and Recovery (PROSPER) Project
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT05456360: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT05456360 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 89 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05456360, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This phase II/III trial examines how a sleep enhancement intervention, including the use of wearable digital vital sign monitoring device (ViSi), affects the quality of life of cancer patients receiving acute care. Sleep enchancement interventions may improve the quality of life of patients with cancer due to fewer interruptions at night during hospital stays.
Interventions
- DEVICE ViSi Mobile device
- DRUG Sleep enhancement intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2023-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05456360
The ClinicalTrials.gov registry entry for NCT05456360 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ViSi Mobile device is the first listed.
NCT05456360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05456360 about?
NCT05456360 is a clinical study titled "Implementation of Digital Vital Sign Monitoring to Decrease Sleep Interruption and Enhance Recovery in Phase II of the PROmoting Sleep, Patient Engagement and Recovery (PROSPER) Project". This phase II/III trial examines how a sleep enhancement intervention, including the use of wearable digital vital sign monitoring device (ViSi), affects the quality of life of cancer patients receiving acute care. Sleep enchancement interventions may improve the quality of life of patients with can...
What is the current status of trial NCT05456360?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2023-03-01. Estimated completion is 2023-10-30.
What interventions are being tested in trial NCT05456360?
The interventions under investigation include: ViSi Mobile device (DEVICE), Sleep enhancement intervention (DRUG).
Who is sponsoring clinical trial NCT05456360?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.